chiniofon and Skin-Diseases

Topics: Amebiasis; Amebicides; Animals; Anti-Bacterial Agents; Brain Abscess; Digestive System Diseases; Emetine; Entamoeba histolytica; Entamoebiasis; Feces; Female; Humans; Hydroxyquinolines; Liver; Liver Abscess, Amebic; Lung Diseases; Male; Metronidazole; Peritonitis; Radionuclide Imaging; Serologic Tests; Skin Diseases; Ultrasonography

Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Betamethasone Valerate; Child; Child, Preschool; Clioquinol; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxyquinolines; Male; Middle Aged; Ointments; Random Allocation; Skin Diseases

Topics: Adolescent; Adult; Clinical Trials as Topic; Dermatitis, Atopic; Drug Evaluation; Female; Halogens; Humans; Hydroxyquinolines; Male; Middle Aged; Oxyquinoline; Skin Diseases

Roquinimex is being used for posttransplantation immunotherapy of autologous bone marrow transplantation for acute and chronic myelogenous leukemia. This immunotherapeutic agent is a cytokine inducer and may induce an autologous graft-versus-host (GVH) and graft-versus-tumor reactions.. Our purpose was to examine patients undergoing this immunotherapy for clinical signs and symptoms of acute GVH reactions and to correlate these symptoms with their clinical outcome.. We studied eight patients receiving requinimex therapy.. We found autologous GVH reactions in three of eight patients (38%) treated with this immunotherapy. Their disease was manifested by localized or widespread violaceous papules that on histologic evaluation were compatible with a grade II GVH reaction. The acute cutaneous GVH reaction was associated with eccrine sweat gland necrosis, a dermatologic toxicity usually associated with chemotherapy.. Long-term studies of larger numbers of patients treated with this immunotherapy will determine whether these GVH reactions confer significant, sustained, antitumor effects.

Topics: Acute Disease; Adjuvants, Immunologic; Bone Marrow Transplantation; Female; Graft vs Host Reaction; Humans; Hydroxyquinolines; Leukemia, Myeloid; Male; Middle Aged; Necrosis; Skin; Skin Diseases; Sweat Glands; Transplantation, Autologous

Topics: Adult; Carcinoma; Child, Preschool; Dermatofibrosarcoma; Drug Eruptions; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granuloma; Hidradenitis; Histiocytosis, Sinus; Humans; Hydroxyquinolines; Lymphatic Diseases; Male; Middle Aged; Myxedema; Nevus; Paraproteinemias; Skin Diseases; Syphilis; Xanthomatosis

Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clioquinol; Dermatologic Agents; Emulsions; Female; Humans; Hydroxyquinolines; Infant; Male; Middle Aged; Skin Diseases

The skin absorption of clioquinol and chloroquinaldol in ointment or cream base was studied in fourteen patients with widespread dermatoses. A serum concentration in the range of 0.3--1.3 microgram/ml using clioquinol and 0.05--0.1 microgram/ml with chloroquinaldol was reached by the second day and persisted throughout the topical treatment. The mean serum half-life of clioquinol and of chloroquinaldol was estimated to 25 and 6 hours, respectively. Local application of zinc oxide ointment after the end of the treatment chelate-bound the skin deposits of clioquinol and lowered the serum half-life to 11 hours. The mean daily urinary excretion of the applied amount of clioquinol and chloroquinaldol was 4.5 and 6%, respectively.

Topics: Administration, Topical; Clioquinol; Female; Half-Life; Humans; Hydroxyquinolines; Male; Skin Absorption; Skin Diseases

Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Local; Antifungal Agents; Betamethasone; Chloroquinolinols; Drug Combinations; Drug Evaluation; Female; Humans; Hydroxyquinolines; Male; Middle Aged; Skin Diseases

Topics: Acne Vulgaris; Benzoyl Peroxide; Drug Combinations; Drug Therapy; Humans; Hydrocortisone; Hydroxyquinolines; Ointments; Oxyquinoline; Peroxides; Quinolines; Skin Diseases